Seonhwa Lee

Seonhwa Lee

Auto-generated profile, based on publicly available information

Seonhwa Lee


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MYMinjae Yoon
Minjae Yoon
SLSeonhwa Lee
Seonhwa Lee
Jah Yeon ChoiJah Yeon Choi
Jah Yeon Choi
MJMi-Hyang Jung
Mi-Hyang Jung
JYJong-Chan Youn
Jong-Chan Youn
DCDong-Ju Choi
Dong-Ju Choi
Background: Current heart failure (HF) guidelines recommend a multidisciplinary approach, discharge education, and self-management for HF. However, the recommendations are challenging to implement in real-world clinical settings. Objective: We developed a mobile health (mHealth) platform for HF self-care to evaluate whether a smartphone app–based intervention with Bluetooth-connected monitoring devices and a feedback system can help improve HF symptoms. Methods: In this prospective, randomized, multicenter study, we enrolled patients 20 years of age and older, hospitalized for acute HF, and who could use a smartphone from 7 tertiary hospitals in South Korea. In the intervention group (n=39), the apps were automatically paired with Bluetooth-connected monitoring devices. The patients could enter information on vital signs, HF symptoms, diet, medications, and exercise regimen into the app daily and receive feedback or alerts on their input. In the control group (n=38), patients could only enter their blood pressure, heart rate, and weight using conventional, non-Bluetooth devices and could not receive any feedback or alerts from the app. The primary end point was the change in dyspnea symptom scores from baseline to 4 weeks, assessed using a questionnaire. Results: At 4 weeks, the change in dyspnea symptom score from baseline was significantly greater in the intervention group than in the control group (mean –1.3, SD 2.1 vs mean –0.3, SD 2.3; P=.048). A significant reduction was found in body water composition from baseline to the final measurement in the intervention group (baseline level mean 7.4, SD 2.5 vs final level mean 6.6, SD 2.5; P=.003). App adherence, which was assessed based on log-in or the percentage of days when symptoms were first observed, was higher in the intervention group than in the control group. Composite end points, including death, rehospitalization, and urgent HF visits, were not significantly different between the 2 groups. Conclusions: The mobile-based health platform with Bluetooth-connected monitoring devices and a feedback system demonstrated improvement in dyspnea symptoms in patients with HF. This study provides evidence and rationale for implementing mobile app–based self-care strategies and feedback for patients with HF. Trial Registration: ClinicalTrials.gov NCT05668000; https://clinicaltrials.gov/study/NCT05668000

7 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SLSeon-Hwa Lee
Seon-Hwa Lee
ICIksung Cho
Iksung Cho
SYSeng Chan You
Seng Chan You
MCMin-Jae Cha
Min-Jae Cha
JCJeesuk Chang
Jeesuk Chang
HKHyo Song Kim
Hyo Song Kim
Backgrounds: There are scarce data on whether immune checkpoint inhibitors (ICIs) increase the risk of cardiac dysfunction when used with cardiotoxic agents. Thus, we evaluated cardiac dysfunction in patients with sarcoma receiving doxorubicin with or without ICI using echocardiography and left ventricular global longitudinal strain (LVGLS). Methods: A total of 95 patients were included in this study. Echocardiography and LVGLS were evaluated at baseline and follow-up (at 3 and 6 months of chemotherapy) and compared with the doxorubicin (Dox; n = 73) and concomitant ICI with doxorubicin (Dox-ICI; n = 22) groups. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a left ventricular ejection fraction (LVEF) drop of >10% and LVEF of 10%, LVEF of ≥50%, and LVGLS relative reduction of >15% (probable CTRCD) at six months. Results: There were no significant differences in age, cumulative dose of doxorubicin, and cardiovascular risk factors between the two groups. At baseline, the LVEF was similar in the Dox and Dox-ICI groups (p = 0.493). In the Dox group, LVEF decreased to 59 ± 6% (Δ −7 ± 1.3%, p < 0.001) and LVGLS decreased from −17.3 ± 3.2% to −15.4 ± 3.2% (Δ −10.1 ± −1.9%, p < 0.001) at six months. In the Dox-ICI group, LVEF decreased to 55 ± 9% (Δ −9 ± 2.1%, p < 0.001), along with a significant decrease in LVGLS (from −18.6 ± 1.9% to −15.3 ± 3.6%, Δ −12.4 ± −2.4%, p < 0.001). Over a median follow-up of 192 days, there were no cases with clinical manifestations of fulminant myocarditis. In the Dox group, definite and probable CTRCD were observed in seven (10.1%) and five (7.4%) patients, respectively. In the Dox-ICI group, definite and probable CTRCD were observed in four (19%) and four (19%) patients, respectively. The total number of patients who developed CTRCD was significantly higher in the Dox-ICI group than in the Dox group (38.1% vs. 17.4%, p = 0.042). Serum troponin-T level was significantly higher in the Dox-ICI group than in the Dox group (53.3 vs. 27.5 pg/mL, p = 0.023). Conclusions: ICIs may increase the risk of CTRCD when used with cardiotoxic agents. CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS.

15 September 2022 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
MCMin Jae Cha
Min Jae Cha
WKWilliam D Kim
William D Kim
HWHoyoun Won
Hoyoun Won
JJJaeeun Joo
Jaeeun Joo
HKHasung Kim
Hasung Kim
ICIksung Cho
Iksung Cho
Korean Circulation Journal 대한심장학회지 순환기 Cha MJ, et al. Korean Circ J. 2022 Sep;52:e91. https://doi.org/10.4070/kcj.2022.0110

1 January 2025 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JHJunho Hyun
Junho Hyun
DPDayoung Pack
Dayoung Pack
MBMinjung Bak
Minjung Bak
HPHyukjin Park
Hyukjin Park
HKHyung Yoon Kim
Hyung Yoon Kim
JYJeong Hoon Yang
Jeong Hoon Yang
Hyun J, et al. Korean Circ J. 2024 Dec;55:e29. https://doi.org/10.4070/kcj.2024.0229

1 January 2025 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
DHDavid Hong
David Hong
MBMinjung Bak
Minjung Bak
HPHyukjin Park
Hyukjin Park
HKHyung Yoon Kim
Hyung Yoon Kim
SLSeonhwa Lee
Seonhwa Lee
JYJeong Hoon Yang
Jeong Hoon Yang
Hong D, et al. Korean Circ J. 2025 May;55:e87. https://doi.org/10.4070/kcj.2024.0445

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HLHee Jeong Lee
Hee Jeong Lee
ICIksung Cho
Iksung Cho
DKDae-Young Kim
Dae-Young Kim
JSJang-Won Son
Jang-Won Son
KCKang-Un Choi
Kang-Un Choi
JNJagat Narula
Jagat Narula
Lee HJ, et al. J Korean Med Sci. 2024 Apr;39(17):e152. https://doi.org/10.3346/jkms.2024.39.e152